Acromegaly Update

Ethan Weiss
  • 0,0 (0)
  • Life Science
  • Varje vecka

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.

Avsnitt

  1. −2 d

    Acromegaly Update — Monday June 15, 2026

    Surgical technique innovation and a JCEM editorial from two giants of the field reshape how we think about curing GH-secreting tumors and managing cancer risk in acromegaly, while the rare disease sector sees a burst of late-stage deal-making and platform financing that signals strong investor conviction in gene-silencing technologies.

    7 min

  2. 8 juni

    Acromegaly Update — Monday June 8, 2026

    A landmark JCEM special issue lands this week with five major reviews and original studies that collectively reset the clinical playbook for acromegaly — from emerging oral therapies to the underappreciated mortality burden — while in the rare disease industry, Alnylam bets $2 billion on AI-designed RNA medicines, a controversial FDA voucher program faces calls for reform, and a new market forecast projects orphan drug sales above $400 billion by 2032.

    13 min

  3. 1 juni

    Acromegaly Update — Monday June 1, 2026

    New Pituitary research this week highlights the cardiac and bone risks that persist even in treated acromegaly patients, while the rare disease industry grapples with a mixed regulatory environment — one notable ASCO data release and continued fallout from FDA leadership turnover.

    7 min

  4. 25 maj

    Acromegaly Update — Monday May 25, 2026

    A network meta-analysis confirms that injectable somatostatin receptor ligands remain first-line in acromegaly, while new clinical data on paltusotine and pasireotide, plus rare disease industry news including BioMarin and Intellia, shape the week.

    7 min

  5. 18 maj

    Acromegaly Update — Monday May 18, 2026

    New proteomic biomarkers could sharpen acromegaly diagnosis beyond GH/IGF-1, while the rare disease industry sees a wave of FDA decisions and high-stakes M&A activity.

    7 min

  6. 11 maj

    Acromegaly Update — Monday May 11, 2026

    Acromegaly research this week centered on the long-term pharmacology of established therapies and clinical management updates, while the rare disease industry absorbed significant regulatory and pipeline news.

    7 min

  7. 7 maj

    Acromegaly Update — Thursday May 7, 2026

    This week's literature brings a long-term safety confirmation for pegvisomant monotherapy, a head-to-head comparison of first-generation somatostatin analogs using a validated composite score, and new evidence linking acromegaly to hepatic steatosis — alongside cost-effectiveness data for pasireotide and updated pituitary tumor pathology tools.

    7 min

  8. 4 maj

    Acromegaly Update — Monday May 4, 2026

    Two important consensus-level papers from late April 2026 sharpen the standards for acromegaly diagnosis and comorbidity management, incorporating AI-assisted screening, ultrasensitive GH assays, and updated international expert guidance.

    7 min

  9. 28 apr.

    Acromegaly Update — Tuesday April 28, 2026

    This week's acromegaly literature is headlined by a landmark cardiovascular disease review in Endocrine Reviews and a cluster of high-yield JCEM papers covering biomarker-guided therapy, standardized pituitary imaging, patient-reported quality of life, and histological predictors of surgical remission.

    7 min
  • 9 avsnitt

Om

Weekly digest of new research on acromegaly — trials, therapies, and clinical updates.

Information

  • Skapad av
    Ethan Weiss
  • Aktiva år
    2 tn
  • Avsnitt
    9
  • Åldersgräns
    Barnvänligt
  • Copyright
    © Ethan Weiss / Marea Therapeutics
  • Programmets webbplats
    Acromegaly Update